title: Dissemination of information on the off-label (unapproved) use of medication: a comparative analysis.
abstract: "Off-label" in relation to the use of medication means that a medicine is used in another way or for indications other than those specified in its conditions of registration and reflected in its labelling. The off-label use of medication accounts for an estimated 21 per cent of drug use overall and is an important part of mainstream, legitimate medical practice worldwide. In South Africa, legislation prohibits the dissemination of information regarding the off-label use of medication. There are diverging views on whether pharmaceutical companies should be allowed to distribute scientific publications on off-label uses of approved drugs. Current policy in the United States of America (USA) eases restrictions on the dissemination of information of this nature. The prohibitions existing in South Africa, however, are more comparable with those in European countries. After analysing the different legal positions on the issue, it is submitted that pharmaceutical companies should not be allowed to disseminate information on off-label uses, but that the regulatory authority play an active and leading role in providing the latest, objective medical and scientific information, as well as guidelines on the off-label use of medication. Other related recommendations are also made.
authors.affiliation: Faculty of Law, University of the Free State, Bloemfontein, South Africa. jansenr@ufs.ac.za
authors.forename: Rita-Marié
authors.initials: RM
authors.lastname: Jansen
mesh_terms: D004345:Drug Industry; D004348:Drug Labeling; D005062:European Union; D006801:Humans; D033181:Information Dissemination / Q000331:legislation & jurisprudence*; D056687:Off-Label Use; D013019:South Africa; D014481:United States